Arcturus Therapeutics Holdings Inc. (ARCT) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
ARCT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ARCT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 95.5% | -111.5% | -97.9% |
| 2024 | 100.0% | -69.1% | -58.5% |
| 2023 | 100.0% | -49.6% | -18.8% |
| 2022 | 100.0% | 5.9% | 4.5% |
| 2021 | 100.0% | -1641.3% | -1648.0% |
Download Data
Export ARCT earnings history in CSV or JSON format
Free sign-in required to download data
Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Overview
As of May 8, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) reported trailing twelve-month net income of -$66M, reflecting +20.0% year-over-year growth. The company earned $-2.40 per diluted share over the past four quarters, with a net profit margin of -97.9%.
Looking at the long-term picture, ARCT's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2022.
Arcturus Therapeutics Holdings Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MRNA (-$3.19B net income, -145.2% margin), BNTX (-$1.13B net income, -39.6% margin), NTLA (-$413M net income, -609.9% margin), ARCT has outperformed on profitability metrics. Compare ARCT vs MRNA →
ARCT Earnings vs Peers
Earnings metrics vs comparable public companies
ARCT Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$66M | +18.7% | -$75M | $-2.40 | -97.9% | -111.5% |
| 2024 | -$81M | -172.3% | -$96M | $-3.00 | -58.5% | -69.1% |
| 2023 | -$30M | -417.9% | -$78M | $-1.12 | -18.8% | -49.6% |
| 2022 | $9M | +104.6% | $12M | $0.35 | 4.5% | 5.9% |
| 2021 | -$204M | -182.3% | -$203M | $-7.74 | -1648.0% | -1641.3% |
| 2020 | -$72M | -177.6% | -$72M | $-3.55 | -756.3% | -749.8% |
| 2019 | -$26M | -19.3% | -$26M | $-2.13 | -125.0% | -122.7% |
| 2018 | -$22M | -99.8% | -$22M | $-2.16 | -138.3% | -138.5% |
| 2017 | -$11M | +55.7% | -$10M | $-3.53 | -83.9% | -80.7% |
| 2016 | -$25M | -26.5% | -$25M | $-6.25 | -120.7% | -123.5% |
See ARCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARCT — Frequently Asked Questions
Quick answers to the most common questions about buying ARCT stock.
Is ARCT growing earnings?
ARCT EPS is $-2.40, with earnings growth accelerating to +20.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-66M.
What are ARCT's profit margins?
Arcturus Therapeutics Holdings Inc. net margin is -97.9%, with operating margin at -111.5%. Below-average margins reflect competitive or cost pressures.
How consistent are ARCT's earnings?
ARCT earnings data spans 2011-2025. The accelerating earnings trend is +20.0% YoY. Historical data enables comparison across business cycles.